Intelligent Investor

EvoGenix Limited (ASX: EGX) - Announcements

DELISTED - Current share price for EGX : $0.750

ASX company news and announcements for EvoGenix Limited (EGX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All EvoGenix Limited (EGX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than EvoGenix Limited (EGX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for EvoGenix Limited (EGX)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Suspension from Official Quotation 20 Aug 2007 2:31PM $0.750 $0.750 $0.750 fallen by 0%
- New project with GlaxoSmithKline 16 Aug 2007 9:21AM $0.750 $0.750 $0.750 fallen by 0%
- Merger - EGX Shareholders Approve EvoGenix - Peptech Merger 9 Aug 2007 12:55PM $0.850 $0.750 $0.750 fallen by 11.76%
- Trading Halt 9 Aug 2007 10:12AM $0.850 $0.750 $0.750 fallen by 11.76%
- Appendix 4C - quarterly 30 Jul 2007 10:00AM $0.900 $0.750 $0.750 fallen by 16.67%
- Peptech and Evogenix merge to form antibody powerhouse 7 May 2007 8:31AM $1.010 $0.750 $0.750 fallen by 25.74%
- Peptech and EvoGenix merge to form antibody powerhouse 7 May 2007 8:31AM $1.010 $0.750 $0.750 fallen by 25.74%
- Commitments Test Entity - Third Quarter Report 26 Apr 2007 3:24PM $0.795 $0.750 $0.750 fallen by 5.66%
- Confirmation of project success by GlaxoSmithKline 26 Mar 2007 8:31AM $0.800 $0.750 $0.750 fallen by 6.25%
- Antibody development collaboration with Vegenics 27 Feb 2007 9:14AM $0.780 $0.750 $0.750 fallen by 3.85%
- Half Yearly Report/Half Yearly Accounts 23 Feb 2007 2:36PM $0.820 $0.750 $0.750 fallen by 8.54%
- Commitments Test Entity - Second Quarter Report 31 Jan 2007 8:28AM $0.900 $0.750 $0.750 fallen by 16.67%
- Granted US patent 24 Jan 2007 8:40AM $0.765 $0.750 $0.750 fallen by 1.96%
- Capital raising completed 7 Dec 2006 10:04AM $0.530 $0.750 $0.750 risen by 41.51%
- Trading Halt 6 Dec 2006 9:35AM n/a $0.750 $0.750 n/a
- To Collaborate with US National Institutes of Health 2 Nov 2006 10:48AM $0.550 $0.750 $0.750 risen by 36.36%
- Commitments Test Entity - First Quarter Report 26 Oct 2006 4:11PM $0.500 $0.750 $0.750 risen by 50%
- Successful testing of Osteoporosis treatment 19 Sep 2006 8:31AM $0.430 $0.750 $0.750 risen by 74.42%
- Preliminary Final Report 29 Aug 2006 8:29AM n/a $0.750 $0.750 n/a
- Commitments Test Entity - Fourth Quarter Report 26 Jul 2006 2:51PM $0.560 $0.750 $0.750 risen by 33.93%
- Offered $1.6m grant for cancer drug program 5 Jul 2006 9:08AM $0.560 $0.750 $0.750 risen by 33.93%
- EvoGenix to collaborate with CSL 1 Jun 2006 9:18AM $0.500 $0.750 $0.750 risen by 50%
- Commitments Test Entity - Third Quarter Report 26 Apr 2006 3:42PM n/a $0.750 $0.750 n/a
- EvoGenix licenses cancer antibody 10 Apr 2006 9:40AM $0.420 $0.750 $0.750 risen by 78.57%
- Half Yearly Report & Half Year Accounts 24 Feb 2006 4:00PM $0.355 $0.750 $0.750 risen by 111.27%

1 - 25 of 32 results

Page 1 of 2

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.